Ras mutations in human pituitary tumors

HJ Karga, JM Alexander… - The Journal of …, 1992 - academic.oup.com
HJ Karga, JM Alexander, ET Hedley-Whyte, A Klibanski, JL Jameson
The Journal of Clinical Endocrinology & Metabolism, 1992academic.oup.com
The cellular basis for pituitary neoplasia is poorly understood. Mutations that activate the ras
protooncogenes have been identified in a number of different types of human cancers and
potentially represent one of the genetic alterations that occur in pituitary tumors. In this study
we examined 19 pituitary tumors for the occurrence of ras mutations. The tumor types
included 11 nonfunctioning adenomas, 6 somatotroph adenomas, and 2 prolactinomas.
Each of the three ras genes (K-ras, N-ras, and H-ras) was amplified from pituitary tumor DNA …
Abstract
The cellular basis for pituitary neoplasia is poorly understood. Mutations that activate the ras protooncogenes have been identified in a number of different types of human cancers and potentially represent one of the genetic alterations that occur in pituitary tumors. In this study we examined 19 pituitary tumors for the occurrence of ras mutations. The tumor types included 11 nonfunctioning adenomas, 6 somatotroph adenomas, and 2 prolactinomas. Each of the three ras genes (K-ras, N-ras, and H-ras) was amplified from pituitary tumor DNA using the polymerase chain reaction. Oligonucleotide-specific hybridization was used to screen for mutations that inhibit GTPase activity and cause activation of the ras oncogene. No ras mutations were observed in 18 of the pituitary adenomas. However, a mutation was identified in codon 12 of the H-ras gene (Gly to Val) in a recurrent prolactinoma that was highly invasive and ultimately proved to be fatal. We conclude that ras mutations are uncommon in pituitary adenomas, but may provide a marker for highly invasive tumors.
Oxford University Press